Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Talk Evidence - Z drugs, subclinical hypothyroidism and Drazen’s dozen

Talk Evidence - Z drugs, subclinical hypothyroidism and Drazen’s dozen

FromThe BMJ Podcast


Talk Evidence - Z drugs, subclinical hypothyroidism and Drazen’s dozen

FromThe BMJ Podcast

ratings:
Length:
45 minutes
Released:
Jun 25, 2019
Format:
Podcast episode

Description

This week on the podcast, (2.02) a listener asks, when we suggest something to stop, should we suggest an alternative instead?

(8.24) Helen tells us to stop putting people on treatment for subclinical hypothyroidism, but what does that mean for people who are already receiving thyroxine?

(20.55) Carl has a black box warning about z drugs, and wonders what the alternative for sleep are.

(30.11) Finally the NEJM has published Jeff Drazen's dozen most influential papers - but not a systematic review amongst them. Cue the rant.

Reading list:
Rapid rec on subclinical hypothyroidism
https://www.bmj.com/content/365/bmj.l2006

Temporal trends in use of tests in UK primary care, 2000-15
https://www.bmj.com/content/363/bmj.k4666

Black box warning for z-drugs
https://www.bmj.com/content/365/bmj.l2165

Drazen's dozen
https://cdn.nejm.org/pdf/Drazens-Dozen.pdf
Released:
Jun 25, 2019
Format:
Podcast episode

Titles in the series (100)

The BMJ is an international peer reviewed medical journal and a fully “online first” publication. The BMJ’s vision is to be the world’s most influential and widely read medical journal. Our mission is to lead the debate on health and to engage, inform, and stimulate doctors, researchers, and other health professionals in ways that will improve outcomes for patients. We aim to help doctors to make better decisions.